Iowa City

The trials here

What the 25 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma4 trials
• Chronic kidney disease3 trials
• Lung cancer3 trials
• Asthma2 trials
• Bladder cancer2 trials
• COPD2 trials
• Follicular lymphoma2 trials
• Acute lymphoblastic leukaemia1 trial
• Atrial fibrillation1 trial
• Childhood cancers1 trial
• Coronary artery disease1 trial
• Dermatomyositis and polymyositis (myositis)1 trial
• and 8 more

Phase

• Phase 315 trials
• Phase 13 trials
• Phase 1/23 trials
• Phase 21 trial
• Phase 41 trial

Status

• Active, not recruiting9 trials
• Recruiting6 trials
• Completed4 trials
• Not yet recruiting3 trials
• Withdrawn2 trials
• Terminated1 trial

Lead sponsor

• AstraZeneca24 trials
• DalCor Pharmaceuticals1 trial

Running trials

• Recruiting

  A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

  NCT07624305· Phase 3· AstraZeneca· Source

  Contact: AstraZeneca Clinical AstraZeneca Clinical

• Recruiting

  Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  NCT07764978· Phase 3· AstraZeneca· Source

• Recruiting

  Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

  NCT07109219· Phase 1/2· AstraZeneca· Source

• Recruiting

  A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

  NCT07073547· Phase 1· AstraZeneca· Source

• Recruiting

  A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

  NCT06916806· Phase 1· AstraZeneca· Source

• Recruiting

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

  NCT06749457· Phase 1/2· AstraZeneca· Source

• Recruiting

  A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

  NCT06549595· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

  NCT06109779· Phase 3· AstraZeneca· Source

• Recruiting

  Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

  NCT05918861· Phase 3· DalCor Pharmaceuticals· Source

  Contact: David Kallend, MBBS

• Recruiting

  AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

  NCT05850234· Phase 1/2· AstraZeneca· Source

• Active, not recruiting

  Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

  NCT05687266· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

  NCT04960709· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

  NCT03953300· Phase 4· AstraZeneca· Source

• Active, not recruiting

  Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

  NCT03833154· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

  NCT03819465· Phase 1· AstraZeneca· Source

• Active, not recruiting

  Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

  NCT03732677· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Savolitinib vs. Sunitinib in MET-driven PRCC.

  NCT03091192· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma3 recruiting
• Chronic kidney disease2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Childhood cancers1 recruiting
• Coronary artery disease1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Follicular lymphoma1 recruiting
• High blood pressure1 recruiting
• Lupus (SLE)1 recruiting
• Rheumatoid arthritis1 recruiting

Closed trials

• Recruiting

  A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  NCT07391657· Phase 3· AstraZeneca· Source

• Recruiting

  Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

  NCT06526793· Phase 2· AstraZeneca· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT05166889· Phase 3· AstraZeneca· Source

• Terminated

  Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

  NCT04847232· Phase 3· AstraZeneca· Source

• Completed

  Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

  NCT04053634· Phase 3· AstraZeneca· Source

• Completed

  A Disease Registry of Patients With Mantle Cell Lymphoma

  NCT03816683· AstraZeneca· Source

• Completed

  Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)

  NCT03373045· AstraZeneca· Source